Wockhardt gets USFDA nod for insomnia drug
Pharmaceutical and biotechnology major Wockhardt received approval from the US regulatory authority for marketing Midazolam injections.
By PTI |
MUMBAI: Pharmaceutical and biotechnology major Wockhardt on Thursday said it has received approval from the US regulatory authority for marketing Midazolam injections, used in the treatment of sleeplessness and anxiety.
In a filing to the Bombay Stock Exchange, Wockhardt said it has received nod from United States Food and Drug Administration (USFDA) for marketing preservative-free version injections containing 1mg/ ml and 5 mg/ml Midazolam.
"Sterile products continue to be a priority area for Wockhardt in the US," company Chairman Habil Khorakiwala said.
This is our fourth injection Abbreviated New Drug Application approval in two months and the 12th sterile product overall.
Wockhardt was trading at Rs 105.60, up 1.15 per cent in the early trade on the BSE.
In a filing to the Bombay Stock Exchange, Wockhardt said it has received nod from United States Food and Drug Administration (USFDA) for marketing preservative-free version injections containing 1mg/ ml and 5 mg/ml Midazolam.
"Sterile products continue to be a priority area for Wockhardt in the US," company Chairman Habil Khorakiwala said.
This is our fourth injection Abbreviated New Drug Application approval in two months and the 12th sterile product overall.
Wockhardt was trading at Rs 105.60, up 1.15 per cent in the early trade on the BSE.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
